Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Nicolosi, Pier Andrea ^a   Tombetti, Enrico ^b   Maugeri, Norma ^b   Rovere Querini, Patrizia ^b   Brunelli, Silvia ^a   Manfredi, Angelo A ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; INTERFERON; MICRORNA; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CELL TRANSFORMATION; ENDOTHELIAL MESENCHYMAL TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; VASCULAR REMODELING; VASCULITIS;

EID: 84962867201     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/4636859     Document Type: Review

References (138)

1. S. Bhattacharyya, J. Wei, and J. Varga, "Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities, " Nature Reviews Rheumatology, vol. 8, no. 1, pp. 42-54, 2012.
2. F. M. Wigley, "Vascular disease in scleroderma, " Clinical Reviews in Allergy and Immunology, vol. 36, no. 2-3, pp. 150-175, 2009.
3. L. A. Saketkoo andO. Distler, "Is there evidence for vasculitis in systemic sclerosis, " Current Rheumatology Reports, vol. 14, no. 6, pp. 516-525, 2012.
4. G. Farina, M. York, C. Collins, and R. Lafyatis, "dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts, " Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 544-550, 2011.
5. S. Lenna, A. G. Farina, V. Martyanov et al., "Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension, " Arthritis and Rheumatism, vol. 65, no. 5, pp. 1357-1366, 2013.
6. G. Stifano, A. J. Affandi, A. L. Mathes et al., "Chronic Tolllike receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis, " Arthritis Research and Therapy, vol. 16, article R136, 2014.
7. L. van Bon, A. J. Affandi, J. Broen et al., "Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis, " New England Journal of Medicine, vol. 370, no. 5, pp. 433-443, 2014.
8. S. Bhattacharyya and J. Varga, "Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis, " Current Rheumatology Reports, vol. 17, article 474, 2015.
9. S. Guiducci, O. Distler, J. H. Distler, and M. Matucci-Cerinic, "Mechanisms of vascular damage in SSc-implications for vascular treatment strategies, " Rheumatology, vol. 47, supplement 5, pp. v18-v20, 2008.
10. R. Lafyatis, "Transforming growth factor-at the centre of systemic sclerosis, " Nature Reviews Rheumatology, vol. 10, no. 12, pp. 706-719, 2014.
11. M. Cutolo and V. Smith, "State of the art on nailfold capillaroscopy: A reliable diagnostic tool and putative biomarker in rheumatologY" Rheumatology, vol. 52, no. 11, Article ID ket153, pp. 1933-1940, 2013.
12. A. Gabrielli, E. V. Avvedimento, and T. Krieg, "Scleroderma, " The New England Journal ofMedicine, vol. 360, no. 19, pp. 1989-2003, 2009.
13. M. Matucci-Cerinic, B. Kahaleh, and F. M. Wigley, "Review: evidence that systemic sclerosis is a vascular disease, " Arthritis and Rheumatism, vol. 65, no. 8, pp. 1953-1962, 2013.
14. C. Beyer, G. Schett, S. Gay, O. Distler, and J. H. W. Distler, "Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis, " Arthritis Research & Therapy, vol. 11, no. 2, article 220, 2009.
15. C. Dees, A. Akhmetshina, P. Zerr et al., "Platelet-derived serotonin links vascular disease and tissue fibrosis, " Journal of Experimental Medicine, vol. 208, no. 5, pp. 961-972, 2011.
16. T. C. Barnes, D. G. Spiller, M. E. Anderson, S. W. Edwards, and R. J. Moots, "Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: A novel target for systemic sclerosis" Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 366-372, 2011.
17. A. Zarbock, T. Kempf, K. C. Wollert, and D. Vestweber, "Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation, " Journal ofMolecularMedicine, vol. 90, no. 4, pp. 353-359, 2012.
18. J. N. Fleming and S. M. Schwartz, "The pathology of scleroderma vascular disease, " Rheumatic Disease Clinics of North America, vol. 34, no. 1, pp. 41-55, 2008.
19. B. Kahaleh, "Vascular disease in scleroderma: mechanisms of vascular injury, " Rheumatic Disease Clinics of North America, vol. 34, no. 1, pp. 57-71, 2008.
20. M. Trojanowska, "Cellular and molecular aspects of vascular dysfunction in systemic sclerosis, " Nature Reviews Rheumatology, vol. 6, no. 8, pp. 453-460, 2010.
21. M. Manetti, S. Guiducci, E. Romano et al., "Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis, " Circulation Research, vol. 109, no. 3, pp. e14-e26, 2011.
22. C. Mazzotta, E. Romano, C. Bruni et al., "Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis, " Arthritis Research and Therapy, vol. 17, no. 1, article 221, 2015.
23. E. Romano, I. Chora, M. Manetti et al., "Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis, " Annals of the Rheumatic Diseases, 2015.
24. A. L. Herrick, "The pathogenesis, diagnosis and treatment of Raynaud phenomenon, " Nature Reviews Rheumatology, vol. 8, no. 8, pp. 469-479, 2012.
25. A. E. Postlethwaite and T. M. Chiang, "Platelet contributions to the pathogenesis of systemic sclerosis, " Current Opinion in Rheumatology, vol. 19, no. 6, pp. 574-579, 2007.
26. J. D. Pauling, V. B. O'donnell, and N. J. Mchugh, "The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis, " Platelets, vol. 24, no. 7, pp. 503-515, 2013.
27. G. A. Ramirez, S. Franchini, P. Rovere-Querini, M. G. Sabbadini, A. A. Manfredi, and N. Maugeri, "The role of platelets in the pathogenesis of systemic sclerosis, " Frontiers in Immunology, vol. 3, article 160, 2012.
28. A. Solanilla, J. Villeneuve, P. Auguste et al., "The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis, " Rheumatology, vol. 48, no. 9, pp. 1036-1044, 2009.
29. M. M. Cerinic, G. Valentini, G. G. Sorano et al., "Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis, " Seminars in Arthritis and Rheumatism, vol. 32, no. 5, pp. 285-295, 2003.
30. A. Rouhiainen, S. Imai, H. Rauvala, and J. Parkkinen, "Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation, "Thrombosis andHaemostasis, vol. 84, no. 6, pp. 1087-1094, 2000.
31. P. Rovere-Querini, A. Capobianco, P. Scaffidi et al., "HMGB1 is an endogenous immune adjuvant released by necrotic cells, " EMBO Reports, vol. 5, no. 8, pp. 825-830, 2004.
32. H. E. Harris, U. Andersson, and D. S. Pisetsky, "HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease, " Nature Reviews Rheumatology, vol. 8, no. 4, pp. 195-202, 2012.
33. H. Yang, H. Wang, S. S. Chavan, and U. Andersson, "High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule, " Molecular Medicine, vol. 21, pp. S6-S12, 2015.
34. M. E. Bianchi and A. A. Manfredi, "Dangers in and out, " Science, vol. 323, no. 5922, pp. 1683-1684, 2009.
35. A. Castiglioni, V. Canti, P. Rovere-Querini, and A. A. Manfredi, "High-mobility group box 1 (HMGB1) as a master regulator of innate immunity, " Cell and Tissue Research, vol. 343, no. 1, pp. 189-199, 2011.
36. U. Andersson and K. J. Tracey, "HMGB1 is a therapeutic target for sterile inflammation and infection, " Annual Review of Immunology, vol. 29, pp. 139-162, 2011.
37. M. E. Bianchi and A. A. Manfredi, "How macrophages ring the inflammation alarm, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 2866-2867, 2014.
38. M. Zhang, Y. Guo, H. Fu et al., "Chop deficiency prevents UUOinduced renal fibrosis by attenuating fibrotic signals originated from Hmgb1/TLR4/NFB/IL-1 signaling, " Cell Death and Disease, vol. 6, Article IDe1847, 2015.
39. Z. Zhu and X. Hu, "HMGB1 induced endothelial permeability promotes myocardial fibrosis in diabetic cardiomyopathy, " International Journal of Cardiology, 2015.
40. L.-C. Li, D.-L. Li, L. Xu et al., "High-mobility group box 1 mediates epithelial-to-mesenchymal transition in pulmonary fibrosis involving transforming growth factor-1/Smad2/3 signaling, " Journal of Pharmacology and Experimental Therapeutics, vol. 354, no. 3, pp. 302-309, 2015.
41. L.-C. Li, J. Gao, and J. Li, "Emerging role of HMGB1 in fibrotic diseases, " Journal of Cellular andMolecularMedicine, vol. 18, no. 12, pp. 2331-2339, 2014.
42. K. Hayakawa, L.-D. D. Pham, Z. S. Katusic, K. Arai, and E. H. Lo, "Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery, " Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 109, no. 19, pp. 7505-7510, 2012.
43. L. Campana, F. Santarella, A. Espositoet al., "LeukocyteHMGB1 is required for vessel remodeling in regenerating muscles, " Journal of Immunology, vol. 192, no. 11, pp. 5257-5264, 2014.
44. A. Yoshizaki, K. Komura, Y. Iwata et al., "Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: Association with disease severity, " Journal of Clinical Immunology, vol. 29, no. 2, pp. 180-189, 2009.
45. N. Maugeri, S. Franchini, L. Campana et al., "Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis, " Autoimmunity, vol. 45, no. 8, pp. 584-587, 2012.
46. N. Maugeri, P. Rovere-Querini, M. Baldini et al., "Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: A Candidate for microvessel injury in sytemic sclerosis, " Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1060-1074, 2014.
47. N. Maugeri, L. Campana, M. Gavina et al., "Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps, " Journal of Thrombosis and Haemostasis, vol. 12, no. 12, pp. 2074-2088, 2014.
48. S. Guiducci, J. H. W. Distler, A. Jüngel et al., "The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis, " Arthritis and Rheumatism, vol. 58, no. 9, pp. 2845-2853, 2008.
49. C. Oyabu, A. Morinobu, D. Sugiyama et al., "Plasma plateletderived microparticles in patients with connective tissue diseases, " Journal of Rheumatology, vol. 38, no. 4, pp. 680-684, 2011.
50. J. H. W. Distler, A. Akhmetshina, C. Dees et al., "Induction of apoptosis in circulating angiogenic cells by microparticles, " Arthritis and Rheumatism, vol. 63, no. 7, pp. 2067-2077, 2011.
51. D. S. Pisetsky, A. J. Ullal, J. Gauley, and T. C. Ning, "Microparticles as mediators and biomarkers of rheumatic disease, " Rheumatology, vol. 51, no. 10, pp. 1737-1746, 2012.
52. L. V. Iversen, S. Ullman, O. Ostergaard et al., "Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis, " BMC Musculoskeletal Disorders, vol. 16, article 191, 2015.
53. E. Venereau, M. Casalgrandi, M. Schiraldi et al., "Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release, " Journal of Experimental Medicine, vol. 209, no. 9, pp. 1519-1528, 2012.
54. G. Hoppe, K. E. Talcott, S. K. Bhattacharya, J. W. Crabb, and J. E. Sears, "Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1, " Experimental Cell Research, vol. 312, no. 18, pp. 3526-3538, 2006.
55. E. Venereau, M. Schiraldi, M. Uguccioni, and M. E. Bianchi, "HMGB1 and leukocyte migration during trauma and sterile inflammation, "Molecular Immunology, vol. 55, no. 1, pp. 76-82, 2013.
56. L. Campana, L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini, "Requirement of HMGB1 for stromal cellderived factor-1/CXCL12-dependent migration of macrophages and dendritic cells, " Journal of Leukocyte Biology, vol. 86, no. 3, pp. 609-615, 2009.
57. M. Vezzoli, P. Castellani, L. Campana et al., "Redox remodeling: A candidate regulator of HMGB1 function in injured skeletal muscle, " Annals of the New York Academy of Sciences, vol. 1209, no. 1, pp. 83-90, 2010.
58. M. Vezzoli, P. Castellani, G. Corna et al., "High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle, " Antioxidants and Redox Signaling, vol. 15, no. 8, pp. 2161-2174, 2011.
59. M. Schiraldi, A. Raucci, L. M. Muñoz et al., "HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4, " The Journal of Experimental Medicine, vol. 209, no. 3, pp. 551-563, 2012.
60. H. Kazama, J.-E. Ricci, J. M. Herndon, G. Hoppe, D. R. Green, and T. A. Ferguson, "Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of highmobility group box-1 protein, " Immunity, vol. 29, no. 1, pp. 21-32, 2008.
61. D. Tang, R. Kang, H. J. Zeh, and M. T. Lotze, "High-mobility group box 1, oxidative stress, and disease, " Antioxidants and Redox Signaling, vol. 14, no. 7, pp. 1315-1335, 2011.
62. D. S. Pisetsky, J. Gauley, and A. J. Ullal, "HMGB1 andmicroparticles as mediators of the immune response to cell death, " Antioxidants and Redox Signaling, vol. 15, no. 8, pp. 2209-2219, 2011.
63. H. Yang, P. Lundbäck, L. Ottosson et al., "Redox modification of cysteine residues regulates the cytokine activity of highmobility group box-1 (HMGB1), " Molecular Medicine, vol. 18, no. 2, pp. 250-259, 2012.
64. P. Castellani, E. Balza, and A. Rubartelli, "Inflammation, DAMPs, tumor development, and progression: A vicious circle orchestrated by redox signaling, " Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1086-1097, 2014.
65. D. S. Pisetsky, "The translocation of nuclear molecules during inflammation and cell death, " Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1117-1125, 2014.
66. T. Spadoni, S. Svegliati Baroni, D. Amico et al., "A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis, " Arthritis and Rheumatology, vol. 67, no. 6, pp. 1611-1622, 2015.
67. G. A. Ramirez, N. Maugeri, M. G. Sabbadini, P. Rovere-Querini, and A. A. Manfredi, "Intravascular immunity as a key to systemic vasculitis: A work in progress, gaining momentum, " Clinical and Experimental Immunology, vol. 175, no. 2, pp. 150-166, 2014.
68. G. A. Ramirez, P. Rovere-Querini, G. Sabbadini, and A. A. Manfredi, "Parietal and intravascular innate mechanisms of vascular inflammation, " Arthritis Research and Therapy, vol. 17, article 16, 2015.
69. S. Vogel, R. Bodenstein, Q. Chen et al., "Platelet-derived HMGB1 is a critical mediator of thrombosis, " The Journal of Clinical Investigation, vol. 125, no. 12, pp. 4638-4654, 2015.
70. I. Ahrens, Y. Chen, D. Topcic et al., "HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi, " Thrombosis and Haemostasis, vol. 114, no. 5, pp. 994-1003, 2015.
71. C. L. Galligan and E. N. Fish, "The role of circulating fibrocytes in inflammation and autoimmunity, " Journal of Leukocyte Biology, vol. 93, no. 1, pp. 45-50, 2013.
72. S. K. Mathai, M. Gulati, X. Peng et al., "Circulatingmonocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype, " Laboratory Investigation, vol. 90, no. 6, pp. 812-823, 2010.
73. H. Sun, Y. Zhu, H. Pan et al., "Netrin-1 regulates fibrocyte accumulation in the decellularized fibrotic scleroderma lung microenvironment and in bleomycin induced pulmonary fibrosis, " Arthritis & Rheumatology, 2016.
74. S. A. Jimenez and S. Piera-Velazquez, "Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or realitY" Matrix Biology, 2016.
75. J. J. Chia and T. T. Lu, "Update on macrophages and innate immunity in scleroderma, " Current Opinion in Rheumatology, vol. 27, no. 6, pp. 530-536, 2015.
76. G. Stifano and R. B. Christmann, "Macrophage involvement in systemic sclerosis: do we need more evidence?" Current Rheumatology Reports, vol. 18, no. 1, article 2, 2016.
77. A. L. Mathes, R. B. Christmann, G. Stifano, A. J. Affandi, T. R. Radstake et al., "Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin, " Annals of the Rheumatic Diseases, vol. 73, no. 10, pp. 1864-1872, 2014.
78. V. D. Steen and T. A. Medsger, "Changes in causes of death in systemic sclerosis, 1972-2002, " Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 940-944, 2007.
79. V. D. Steen and T. A. Medsger Jr., "Long-term outcomes of scleroderma renal crisis, " Annals of Internal Medicine, vol. 133, no. 8, pp. 600-603, 2000.
80. M. Hudson, "Scleroderma renal crisis, " Current Opinion in Rheumatology, vol. 27, no. 6, pp. 549-554, 2015.
81. P. J. Cannon, M. Hassar, D. B. Case, W. J. Casarella, S. C. Sommers, and E. C. LeRoy, "The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation, " Medicine, vol. 53, no. 1, pp. 1-46, 1974.
82. C. Meune, O. Vignaux, A. Kahan, and Y. Allanore, "Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies, " Archives of Cardiovascular Diseases, vol. 103, no. 1, pp. 46-52, 2010.
83. N. Galiè, M. Humbert, J. Vachiery et al., "2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, " European Respiratory Journal, vol. 46, no. 4, pp. 903-975, 2015.
84. A. Vonk-Noordegraaf, F. Haddad, K. M. Chin et al., "Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology, " Journal of the American College of Cardiology, vol. 62, no. 25, pp. D22-D33, 2013.
85. V. V. McLaughlin, K. W. Presberg, R. L. Doyle et al., "Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, " Chest, vol. 126, no. 1, pp. 78S-92S, 2004.
86. S. Chatterjee, "Pulmonary hypertension in systemic sclerosis, " Seminars in Arthritis and Rheumatism, vol. 41, no. 1, pp. 19-37, 2011.
87. S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky, and S. E. Kimmel, "Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis, " Chest, vol. 123, no. 2, pp. 344-350, 2003.
88. M. R. Fisher, S. C. Mathai, H. C. Champion et al., "Clinical differences between idiopathic and scleroderma-related pulmonary hypertension, " Arthritis and Rheumatism, vol. 54, no. 9, pp. 3043-3050, 2006.
89. E. M. T. Lau, A. Manes, D. S. Celermajer, and N. Galié, "Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward, " European Heart Journal, vol. 32, no. 20, pp. 2489-2498, 2011.
90. P. M. Hassoun, R. T. Zamanian, R. Damico et al., "Ambrisentan and tadalafil up-front combination therapy in sclerodermaassociated pulmonary arterial hypertension, " American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 9, pp. 1102-1110, 2015.
91. N. Galie, J. A. Barbera, A. E. Frost et al., "Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension, " The New England Journal of Medicine, vol. 373, no. 9, pp. 834-844, 2015.
92. E. Stacher, B. B. Graham, J. M. Hunt et al., "Modern age pathology of pulmonary arterial hypertension, " American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 3, pp. 261-272, 2012.
93. P. Dorfmüller, M. Humbert, F. Perros et al., "Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases, " Human Pathology, vol. 38, no. 6, pp. 893-902, 2007.
94. J. C. Mason, "Takayasu arteritis-advances in diagnosis and management, " Nature Reviews Rheumatology, vol. 6, no. 7, pp. 406-415, 2010.
95. C. M. Weyand and J. J. Goronzy, "Giant-cell arteritis and polymyalgia rheumatica, "The New England Journal ofMedicine, vol. 371, no. 1, pp. 50-57, 2014.
96. E. Tombetti, S. Franchini, M. Papa, M. G. Sabbadini, and E. Baldissera, "Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center, " The Journal of Rheumatology, vol. 40, no. 12, pp. 2047-2051, 2013.
97. E. Tombetti, M. C. Di Chio, S. Sartorelli et al., "Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis, " Arthritis Research and Therapy, vol. 16, article 479, 2014.
98. E. Tombetti, M. C. Di Chio, S. Sartorelli et al., "Procalcitonin in takayasu arteritis, "The Journal of Rheumatology, vol. 41, no. 7, pp. 1564-1566, 2014.
99. J. S. Duffield, M. Lupher, V. J. Thannickal, and T. A. Wynn, "Host responses in tissue repair and fibrosis, " Annual Review of Pathology: Mechanisms of Disease, vol. 8, pp. 241-276, 2013.
100. J. He, Y. Xu, D. Koya, and K. Kanasaki, "Role of the endothelialto-mesenchymal transition in renal fibrosis of chronic kidney disease, " Clinical and Experimental Nephrology, vol. 17, no. 4, pp. 488-497, 2013.
101. F. Rieder, S. P. Kessler, G. A. West et al., "Inflammation-induced endothelial-to-mesenchymal transition: A novel mechanism of intestinal fibrosis, " The American Journal of Pathology, vol. 179, no. 5, pp. 2660-2673, 2011.
102. R. Kramann, D. P. Dirocco, and B. D. Humphreys, "Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease, " Journal of Pathology, vol. 231, no. 3, pp. 273-289, 2013.
103. F. A. Mendoza, S. Piera-Velazquez, J. L. Farber, C. Feghali-Bostwick, and S. A. Jiménez, "Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue frompatients with systemic sclerosis-associated interstitial lung disease, " Arthritis & Rheumatism, vol. 68, no. 1, pp. 210-217, 2016.
104. P. Pessina, Y. Kharraz, M. Jardiét al., "Fibrogenic cell plasticity blunts tissue regeneration and aggravates muscular dystrophy, " Stem Cell Reports, vol. 4, no. 6, pp. 1046-1060, 2015.
105. Z. Li and S. A. Jimenez, "Protein kinase C and c-Abl kinase are required for transforming growth factor induction of endothelial-mesenchymal transition in vitro, " Arthritis and Rheumatism, vol. 63, no. 8, pp. 2473-2483, 2011.
106. J. Wei, F. Fang, A. P. Lam et al., "Wnt/-catenin signaling is hyperactivated in systemic sclerosis and induces Smaddependent fibrotic responses in mesenchymal cells, " Arthritis and Rheumatism, vol. 64, no. 8, pp. 2734-2745, 2012.
107. C. Beyer, A. Schramm, A. Akhmetshina et al., "-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis, " Annals of the Rheumatic Diseases, vol. 71, no. 5, pp. 761-767, 2012.
108. A. P. Lam, J. D. Herazo-Maya, J. A. Sennello et al., "Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical CareMedicine, vol. 190, no. 2, pp. 185-195, 2014.
109. A. Akhmetshina, K. Palumbo, C. Dees et al., "Activation of canonical Wnt signalling is required for TGF-mediated fibrosis, " Nature Communications, vol. 3, article 735, 2012.
110. V. Aumiller, N. Balsara, J. Wilhelm, A. Günther, and M. Königshoff, "WNT/-catenin signaling induces IL-1 expression by alveolar epithelial cells in pulmonary fibrosis, "American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 1, pp. 96-104, 2013.
111. M. Königshoff, N. Balsara, E.-M. Pfaff et al., "Functional Wnt signaling is increased in idiopathic pulmonary fibrosis, " PLoS ONE, vol. 3, no. 5, Article ID e2142, 2008.
112. R. Lemaire, G. Farina, J. Bayle et al., "Antagonistic effect of the matricellular signaling protein CCN3 on TGF-andWntmediated fibrillinogenesis in systemic sclerosis and Marfan syndrome, " Journal of Investigative Dermatology, vol. 130, no. 6, pp. 1514-1523, 2010.
113. W. J. Lee, J. H. Park, J. U. Shin et al., "Endothelial-tomesenchymal transition induced byWnt 3a in keloid pathogenesis, " Wound Repair and Regeneration, vol. 23, no. 3, pp. 435-442, 2015.
114. Y. X. Fu, A. Chang, L. Chang et al., "Differential regulation of transforming growth factor signaling pathways by notch in human endothelial cells, " The Journal of Biological Chemistry, vol. 284, no. 29, pp. 19452-19462, 2009.
115. C. Beyer and J. H. W. Distler, "Morphogen pathways in systemic sclerosis, " Current Rheumatology Reports, vol. 15, no. 1, article 299, 2013.
116. P. Cipriani, P. Di Benedetto, P. Ruscitti et al., "The endothelialmesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-and may be blocked by macitentan, a dual endothelin-1 receptor antagonist, " Journal of Rheumatology, vol. 42, no. 10, pp. 1808-1816, 2015.
117. T. J. Corte, G. J. Keir, K. Dimopoulos et al., "Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia, " American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 208-217, 2014.
118. I. Chrobak, S. Lenna, L. Stawski, and M. Trojanowska, "Interferon-promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) 2, " Journal of Cellular Physiology, vol. 228, no. 8, pp. 1774-1783, 2013.
119. H. Zhu, H. Luo, and X. Zuo, "MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma, " Experimental andMolecularMedicine, vol. 45, no. 9, article e41, 2013.
120. X. Deng, Y. Su, H. Wu et al., "The role of microRNAs in autoimmune diseases with skin involvement, " Scandinavian Journal of Immunology, vol. 81, no. 3, pp. 153-165, 2015.
121. I. Kajihara, M. Jinnin, K. Yamane et al., "Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts, " American Journal of Pathology, vol. 180, no. 2, pp. 703-714, 2012.
122. R. Kumarswamy, I. Volkmann, V. Jazbutyte, S. Dangwal, D.-H. Park, and T. Thum, "Transforming growth factor-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 2, pp. 361-369, 2012.
123. A. K. Ghosh, V. Nagpal, J. W. Covington, M. A. Michaels, and D. E. Vaughan, "Molecular basis of cardiac endothelialto-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT, " Cellular Signalling, vol. 24, no. 5, pp. 1031-1036, 2012.
124. V. Nagpal, R. Rai, A. T. Place et al., "MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis, " Circulation, vol. 133, no. 3, pp. 291-301, 2015.
125. N. Altorok, N. Almeshal, Y. Wang, and B. Kahaleh, "Epigenetics, the holy grail in the pathogenesis of systemic sclerosis, " Rheumatology, vol. 54, no. 10, pp. 1759-1770, 2015.
126. I. Montorfano, A. Becerra, R. Cerro et al., "Oxidative stress mediates the conversion of endothelial cells intomyofibroblasts via a TGF-beta1 and TGF-beta2-dependent pathway, " Laboratory Investigation, vol. 94, no. 10, pp. 1068-1082, 2014.
127. S. Piera-Velazquez and S. A. Jimenez, "Role of cellular senescence andNOX4-mediated oxidative stress in systemic sclerosis pathogenesis, " Current Rheumatology Reports, vol. 17, no. 1, article 473, 2015.
128. V. I. Dumit, V. Küttner, J. Käppler et al., "Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts, " Journal of Investigative Dermatology, vol. 134, no. 9, pp. 2321-2330, 2014.
129. P. Cipriani, S. Guiducci, I. Miniati et al., "Impairment of endothelial cell differentiation frombonemarrow-derivedmesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis, " Arthritis and Rheumatism, vol. 56, no. 6, pp. 1994-2004, 2007.
130. B. Eckes, P. Moinzadeh, G. Sengle, N. Hunzelmann, and T. Krieg, "Molecular and cellular basis of scleroderma, " Journal of Molecular Medicine, vol. 92, no. 9, pp. 913-924, 2014.
131. J. R. Moonen, E. S. Lee, M. Schmidt et al., "Endothelialto-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress, " Cardiovascular Research, vol. 108, no. 3, pp. 377-386, 2015.
132. K. Lin, P.-P. Hsu, B. P. Chen et al., "Molecular mechanism of endothelial growth arrest by laminar shear stress, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9385-9389, 2000.
133. D. O'Kane, M. V. Jackson, A. Kissenpfennig et al., "SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitro, " Experimental Dermatology, vol. 23, no. 7, pp. 497-503, 2014.
134. M. Zeisberg, C. Yang, M. Martino et al., "Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition, " The Journal of Biological Chemistry, vol. 282, no. 32, pp. 23337-23347, 2007.
135. K. K. Kim, M. C. Kugler, P. J. Wolters et al., "Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13180-13185, 2006.
136. J. Nikitorowicz-Buniak, C. P. Denton, D. Abraham, and R. Stratton, "Partially evoked epithelial-mesenchymal transition (EMT) is associated with increased TGF signaling within lesional scleroderma skin, " PLoS ONE, vol. 10, no. 7, Article ID e0134092, 2015.
137. Y. Wang, P.-S. Fan, and B. Kahaleh, "Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts, " Arthritis and Rheumatism, vol. 54, no. 7, pp. 2271-2279, 2006.
138. T. Taniguchi, Y. Asano, K. Akamata et al., "Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice, " Arthritis & Rheumatology, vol. 67, no. 2, pp. 517-526, 2015.